Addendum
Polatuzumab vedotin (relapsed or refractory DLBCL) – Addendum to Project A23-140
Report documents
-
Addendum
Polatuzumab vedotin (relapsed or refractory DLBCL) – Addendum to Project A23-140
Additional information
Federal Joint Committee (G-BA)
2024-06-20 A G-BA decision was published.
Project details
- Project no.
- G24-09
- Commission
- Commission awarded on 07.05.2024 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Health Economics
- Topic
- Cancer
- Note
-
If, in the course of the discussions on a commission of the GBA, a need for further revision arises, IQWiG submits an addendum. The GBA decides on the number of patients in the SHI target population.
- DOI
https://dx.doi.org/10.60584/G24-09
Connected Projects
-
Dossier assessment
Polatuzumab vedotin (relapsed or refractory DLBCL) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed